The Flawed Design of Medicare Part D: A Copaxone Case Study Ben LinkAugust 12, 2020Copaxone, glatiramer, Medicare, Part D, PBM, specialty drugs, Gleevec, ACA, Drug prices, Teva, Mylan, Sandoz, Deductible, Rebates, DIR fees
